The Southwood Group are advising clients on A.P Moeller-Maersk A/S as the world's largest shipping line announces rising earnings forecasts for the year.
PharmaVOICE 100, a top publication of the pharmaceutical industry, has announced their prestigious list of honorees for 2013, which includes a leader in nutraceutical research and technology. Dr. Jay Udani, CEO of Medicus Research, is renowned internationally for his innovative research studies on natural health products.
Study Scavenger, the first bilingual smartphone app to allow subjects to search for clinical research studies that meet their health, travel and financial needs, and CenterWatch, a leading provider of clinical research business information and online publisher of active clinical trial listings for patients and the public, are partnering to provide sponsors, contract research organizations (CROs), research centers and patients a mobile solution to their clinical trial needs.
Hendren Group have been watching with interest as Japanese automobile manufacturers, Nissan, resurrect their affordable Datsun brand, aimed primarily at the rapidly growing Indian market for low cost vehicles.
Avail is conducting a Phase 2, randomized clinical study to evaluate the efficacy and safety of a new drug in female Subjects with diarrhea-predominant Irritable Bowel Syndrome (IBS).
Charles H. Hennekens, MD, DrPH, the first Sir Richard Doll professor and senior academic advisor to the dean in the Charles E. Schmidt College of Medicine at Florida Atlantic University collaborates on most comprehensive analyses of NSAIDs and coxibs.
Achieve Clinical is Conducting a Double-Blinded, Randomized, Placebo-Controlled, Proof of Concept Phase 2a Study Exploring the Safety and Efficacy of a New Drug for the Treatment of Patients with Fibromyalgia.
Avail Clinical is conducting an 11-week, Phase 2 Multicenter, Randomized, Double−Blind, Parallel−Group, Placebo−Controlled Study of a new drug in Subjects with Fibromyalgia (FM).
The Second International Conference on E-Learning and E-Technologies in Education (ICEEE2013) will be held at Technical University of Lodz, Poland from Sept. 23- 25, 2013.
The Ayden Rae Foundation has designated the second week in June (June 9 - 15, 2013) as HG Awareness Week, where the community is encouraged to spread the word about this devastating disorder throughout the world.
Vascular BioSciences announces the publication of "Vascular Histomolecular Analysis By Sequential Endoarterial Biopsy in a Shunt Model of Pulmonary Hypertension" to the current issue of the Pulmonary Circulation, Volume 3, Number 1, January to March 2013. Details how percutaneous pulmonary endoarterial biopsy coupled with histologic and molecular analysis represents a potential model of diagnosis.
A Phase 3/4, Multi-Center, Randomized, Double-Blind, Placebo Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Adult Subjects of Black Race with Systemic Lupus Erythematosus (SLE).
A randomized, double-blind, placebo-controlled Phase III Trial to evaluate immunogenicity and safety of three consecutive production lots of the IMVAMUNE® smallpox vaccine in healthy subjects.
This study is a Phase 3, Randomized, Placebo-Controlled, Double-Blind Trial to Assess the Safety, Tolerability and Immunogenicity of a new Meningococcal Vaccine When Given in Healthy Subjects Age 11 to 26.
Dr. Diana Driscoll, President of Genetic Disease Investigators, LLC., in conjunction with Total Eye Care, is beginning FREE pre-clinical trials in search of a cure for "Invisible Illnesses". These may include Chronic Fatigue Syndrome, Multiple Sclerosis, Ehlers-Danlos syndrome with Dysautonomia, Rheumatoid Arthritis, Endometriosis, and Chronic Lyme Disease.
This is a global, multi-center, randomized, placebo-controlled study to evaluate adverse events of special interest in adults with active, autoantibody-positive systemic lupus erythematosus (SLE) treated with a new drug plus standard therapy vs placebo plus standard therapy.
The primary objective of this study is to evaluate the 24-hour spirometric effect (FEV1) of a new drug over a 12-week treatment period in subjects with COPD.
The primary objective of this 22 week study is to investigate the change in glycosylated hemoglobin (HbA1c) after receiving the new drug, as compared to those receiving a placebo.
The primary objective of this study is to evaluate the efficacy of a new drug compared with a placebo in opioid-experienced and opioid-naive subjects with moderate-to-severe Chronic Lower Back Pain.
Confluent Translations is excited to continue our support of MAGI's Clinical Research Conferences and will be exhibiting at the San Diego Conference October 21st through 24th.
The primary objectives of this study are to evaluate the 12-week safety, antiviral activity and tolerability of this new Hep C drug when given in combination with PEG and RIBA as measured by extended rapid virologic response.
The objective of this study is to evaluate the safety and efficacy of a new Rheumatoid Arthritis monotherapy in moderate to severe Rheumatoid Arthritis (RA) subjects.
DISTALZ, the research laboratory specialising in Alzheimer's disease, which is based in the Lille region, has recently been certified as a Laboratory of Excellence by the French government.
Satisfied Users & 
Approved Press Releases
